13 May 2022 - Hundreds of people with a form of the most common form of lung cancer could survive twice as long with the disease, thanks to a drug now available on the NHS.
The drug, durvalumab, can double the overall time someone can survive with an aggressive form of lung cancer from two and a half to five years.